Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 995-1006

  Godley, Lucy A ^a   Njiaju, Uchenna O ^a   Green, Margaret ^a   Weiner, Howard ^a   Lin, Shang ^a   Odenike, Olatoyosi ^a   Rich, Elizabeth S ^a   Artz, Andrew ^a   Van Besien, Koen ^a   Daugherty, Christopher K ^a   Zhang, Yanming ^a   Le Beau, Michelle M ^a   Stock, Wendy ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

High dose cytarabine; Mitoxantrone; Therapy related myeloid neoplasm

Indexed keywords

CYTARABINE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDUCED CANCER; FEBRILE NEUTROPENIA; FEMALE; HEART VENTRICLE FAILURE; HUMAN; INFECTION; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; THERAPY RELATED MYELOID LEUKEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; BONE MARROW CELL; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS, SECOND PRIMARY; NEUTROPENIA; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; MYELOID CELLS; NEOPLASMS, SECOND PRIMARY; NEUTROPENIA; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953493766     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003763468     Document Type: Article

References (30)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937-951.
2. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52.
3. Olney HJ, Mitelman F, Johansson B, Mrozek K, Berger R, Rowley JD. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:413-423. (Pubitemid 34208802)
4. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822-828.
5. Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000;71:144-152.
6. Godley LA, Larson RA. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In: Bennett JM, editor. The myelodysplastic syndromes: pathobiology and clinical management. New York: Marcel Dekker; 2002. pp 139- 176.
7. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997;89:2578-2585.
8. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000;18:963-971.
9. Hale GA, Heslop HE, Bowman LC, et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999;24:735-739.
10. Kroger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006;37:183-189.
11. Devemy E, Li B, Tao M, et al. Poor prognosis acute myelogenous leukemia: 3-biological and molecular biological changes during remission induction therapy. Leuk Res 2001;25:783-791.
12. Linker CA, Owzar K, Powell B, et al. Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplant 2009;44:353-359.
13. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728-5738.
14. Rich ES, Artz A, Karrison T, et al. Allogeneic hematopoietic cell transplantation from combined haploidentical family members and unrelated cord blood (CB) can benefit high risk patients lacking HLA-identical donors. Blood 2009; 114(Suppl. 1):(Abstract 3378).
15. van Besien K, Kline J, Godley LA, et al. Phase I-II study of clofarabine-melphalan-alemtuzumab (CMA) conditioning for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies: determination of MTD and outcomes. Blood 2009;114(Suppl. 1): (Abstract 197).
16. O'Donnell PH, Artz AS, Undevia SD, et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplantation. Submitted.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: 373-383.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Cox D. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
20. Haferlach T, Kern W, Schoch C, et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004;89: 408-418.
21. Preisler HD, Venugopal P, Gregory SA, et al. Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). Leuk Res 2000;24:671-680. (Pubitemid 30495501)
22. Seiter K, Liu D, Feldman E, et al. Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma 2006;47:425-432.
23. Buchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24:2480-2489.
24. Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009;113: 3903-3910.
25. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61-69.
26. Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk Res 2010;34:487-491.
27. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC- 833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004;22:4290-4301.
28. Weiss M, Maslak P, Feldman E, et al. Cytarabine with highdose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996;14:2480-2485.
29. Damon LE, Wolf JL, Rugo HS, et al. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 2000; 26:257-268.
30. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33:395-400.